{"id":"smallpox-and-mpox-vaccine","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Injection site reaction (erythema, induration, pain)"},{"rate":"10-30","effect":"Fever"},{"rate":"10-20","effect":"Myalgia"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108688","moleculeType":"Vaccine component"},"_dailymed":{"setId":"f8b2634b-ccd7-4a42-8db3-26ba9e9627e6","title":"ACAM2000 (SMALLPOX AND MPOX (VACCINIA) VACCINE, LIVE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION DILUENT FOR ACAM2000 (DILUENT FOR SMALLPOX AND MPOX (VACCINIA) VACCINE, LIVE) SOLUTION [EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains live attenuated vaccinia virus (ACAM2000) or recombinant vaccinia virus (JYNNEOS/Imvanex), which triggers both cellular and humoral immune responses against orthopoxviruses. This generates protective antibodies and T-cell immunity that prevent infection or reduce disease severity upon exposure to smallpox or mpox.","oneSentence":"This vaccine stimulates the immune system to recognize and respond to smallpox and mpox viruses by presenting viral antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:54:18.431Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smallpox prevention and post-exposure prophylaxis"},{"name":"Mpox (monkeypox) prevention and post-exposure prophylaxis"}]},"trialDetails":[{"nctId":"NCT05740982","phase":"PHASE2","title":"A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-03-22","conditions":"Monkeypox","enrollment":450},{"nctId":"NCT05879965","phase":"","title":"Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2022-10-06","conditions":"Monkeypox","enrollment":345},{"nctId":"NCT06844500","phase":"PHASE3","title":"Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jean-Pierre Van geertruyden","startDate":"2025-06-23","conditions":"Neonate, Maternal Transmission, Mpox","enrollment":359},{"nctId":"NCT07253675","phase":"PHASE2","title":"Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute Of Biological Products","startDate":"2025-12-31","conditions":"Monkeypox (Mpox)","enrollment":180},{"nctId":"NCT06549530","phase":"PHASE2","title":"Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2024-10-21","conditions":"Monkeypox (Mpox)","enrollment":460},{"nctId":"NCT07093489","phase":"","title":"Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2025-09-30","conditions":"Mpox (Monkeypox), Mpox","enrollment":11990},{"nctId":"NCT06223919","phase":"PHASE3","title":"Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universidad Nacional de Colombia","startDate":"2023-12-16","conditions":"Monkeypox","enrollment":8686},{"nctId":"NCT06844487","phase":"PHASE3","title":"Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC","status":"RECRUITING","sponsor":"Jean-Pierre Van geertruyden","startDate":"2025-05-29","conditions":"Mpox (Monkeypox), Vaccination, Immunogenicity","enrollment":344},{"nctId":"NCT06839989","phase":"PHASE2","title":"An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa, DRC","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2025-08-04","conditions":"Mpox (Monkeypox)","enrollment":600},{"nctId":"NCT05745987","phase":"PHASE4","title":"Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT","status":"RECRUITING","sponsor":"McMaster University","startDate":"2024-09-17","conditions":"Monkeypox","enrollment":3000},{"nctId":"NCT04957485","phase":"PHASE2","title":"Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS","status":"ACTIVE_NOT_RECRUITING","sponsor":"SIGA Technologies","startDate":"2022-04-05","conditions":"Smallpox","enrollment":100},{"nctId":"NCT02977715","phase":"PHASE3","title":"JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-02-23","conditions":"Monkeypox Virus Infection","enrollment":1600},{"nctId":"NCT06829238","phase":"PHASE4","title":"Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-07","conditions":"Systemic Inflammation, Immune Dysregulation, Injection Drug Use","enrollment":100},{"nctId":"NCT05522296","phase":"","title":"Break-through Infection Following Mpox vaccinatIon","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2022-09-12","conditions":"Mpox","enrollment":3125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JYNNEOS"],"phase":"marketed","status":"active","brandName":"Smallpox and Mpox Vaccine","genericName":"Smallpox and Mpox Vaccine","companyName":"SIGA Technologies","companyId":"siga-technologies","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to recognize and respond to smallpox and mpox viruses by presenting viral antigens. Used for Smallpox prevention and post-exposure prophylaxis, Mpox (monkeypox) prevention and post-exposure prophylaxis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}